Scarica l'app Stockscreener
5.21
0.00%
0.00
Dopo l'orario di chiusura:
5.20
-0.010
-0.19%
Precedente Chiudi:
$5.21
Aprire:
$5.2
Volume 24 ore:
248.54K
Relative Volume:
0.44
Capitalizzazione di mercato:
$235.13M
Reddito:
-
Utile/perdita netta:
$-32.74M
Rapporto P/E:
-6.3537
EPS:
-0.82
Flusso di cassa netto:
$-24.89M
1 W Prestazione:
+0.58%
1M Prestazione:
+1.17%
6M Prestazione:
-59.17%
1 anno Prestazione:
-61.83%
Intervallo 1D:
$5.195
$5.23
Intervallo di 1 settimana:
$5.17
$5.23
Portata 52W:
$3.18
$16.02
Third Harmonic Bio Inc Stock (THRD) Company Profile
Nome
Third Harmonic Bio Inc
Settore
Industria
Telefono
(209) 727-2457
Indirizzo
1700 MONTGOMERY STREET, SAN FRANCISCO
Confronta THRD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
5.21 | 233.76M | 0 | -32.74M | -24.89M | -0.82 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Downgrade | Stifel | Buy → Hold |
| 2025-02-12 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-11 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2024-08-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-07 | Iniziato | Raymond James | Outperform |
| 2022-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | Iniziato | Cowen | Outperform |
| 2022-10-10 | Iniziato | Jefferies | Buy |
| 2022-10-10 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Third Harmonic Bio Inc Borsa (THRD) Ultime notizie
Third Harmonic Bio Reports Q1 2025 Financial Results - TipRanks
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Cancer drugmaker iTeos to shut down - BioPharma Dive
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
It’s been three months without a biotech IPO - Endpoints News
THIRD HARMONIC BIO Earnings Results: $THRD Reports Quarterly Earnings - Nasdaq
Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Third Harmonic Bio Announces Plan of Liquidation and Dissolution - ADVFN
Here’s Why Third Harmonic Bio (THRD) Fell in Q1 - Insider Monkey
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down - MSN
Third Harmonic Bio CSO steps down, enters separation agreement - Investing.com Australia
Third Harmonic Bio CSO steps down, enters separation agreement By Investing.com - Investing.com India
Dupixent bounces back in treating hives with FDA approval - BioWorld MedTech
New fund Alis offers struggling biotechs an off-ramp: Finance Report - BioCentury
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
SF biotech company, once worth nearly $1 billion, plans to shut down - SFGATE
Biotech Alert: Searches spiking for these stocks today - TipRanks
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Third Harmonic Bio (THRD) Seeks Stockholder Approval for Liquida - GuruFocus
Third Harmonic Bio plans to liquidate the company, sell urticaria treatment - MSN
Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties - TipRanks
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered - MSN
$26bn Brighton Jones hires new CFO - Citywire
Third Harmonic Bio plans liquidation and asset sale By Investing.com - Investing.com South Africa
Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Higher In Monday's Pre-Market Session (CORRECTED) - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Third Harmonic outlines plans for dissolution - BioPharma Dive
Third Harmonic Bio sees initial distribution of $5.13-$5.33 from liquidation - TipRanks
Third Harmonic Bio stock holds as liquidation plan unveiled By Investing.com - Investing.com Canada
Third Harmonic Bio Stock Is Up 40% Monday: What's Happening?Third Harmonic Bio (NASDAQ:THRD) - Benzinga
Third Harmonic Announces Liquidation And Cash Return, Stock Jumps - Nasdaq
Third Harmonic to shutter; Future Pak once again targets Theratechnologies - Endpoints News
THRD’s Ambitious Moves: From Trials to Strategies? - timothysykes.com
Third Harmonic Bio Plans Liquidation With Lucrative Payouts - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Third Harmonic Bio announces plan of liquidation and dissolution - TipRanks
Third Harmonic Seeks to Liquidate, Dissolve Company - marketscreener.com
Third Harmonic Bio Announces Plan Of Liquidation And Dissolution - marketscreener.com
Third Harmonic Bio plans liquidation and asset sale - Investing.com Australia
Third Harmonic Bio Inc Azioni (THRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):